Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BLOPRESS®
Candesartan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Candesartan QD + Heart Failure Therapy | EXPERIMENTAL | (with angiotensin-converting enzyme-inhibitors/beta-blockers) |
| Placebo QD + Heart Failure Therapy | PLACEBO_COMPARATOR | (with angiotensin-converting enzyme-inhibitors/beta-blockers) |
| Name | Type | Description |
|---|---|---|
| Candesartan | DRUG | Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks. |
| Placebo | DRUG | Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks. |
Inclusion Criteria: * Diabetes mellitus type 2 - insulin dependent or orally treated or managed by diet for at least 3 Months. * Normotension or controlled hypertension with sitting Systolic Blood Pressure less than 140 mmHg and/or sitting Diastolic Blood Pressure less than 90 mmHg. * Regular sinus...
Top 16 of 30 competitors
Candesartan is a small molecule developed by Takeda Pharmaceutical Company Limited for heart failure. It has been studied in a Phase 3 trial in Germany evaluating its efficacy in symptomatic heart failure in diabetic and hypertensive patients. The trial enrolled 22 participants and has been completed.
Candesartan targets AGTR1, the angiotensin II receptor type 1. It acts as an antagonist at this receptor, blocking the actions of angiotensin II. This mechanism is relevant to its development for heart failure, a cardiovascular condition.
Candesartan is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is responsible for its clinical development in heart failure.
Candesartan is in Phase 3 development for heart failure. One Phase 3 trial has been completed, and there are currently no active trials listed. It is an investigational agent in this context.
Candesartan has been studied in a completed Phase 3 trial, NCT00775840, titled 'Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.' The trial was conducted in Germany, enrolled 22 participants, and was randomized, double-blind, and placebo-controlled.